You Can't Call It Cheatin': FDA Draft Guidance Provides a Framework f…

FDA issued draft guidance on 2 June 2026 allowing developers of genome editing therapies to reuse prior knowledge—both public science and proprietary platform data—across chemistry, manufacturing, nonclinical, and clinical development to streamline regulatory approval and reduce duplicative testing. If you're building a genome editing therapy for a rare disease, FDA just cut the time and cost of proving safety by letting you reuse nonclinical and manufacturing data from your previous program—as long as you can show the edits and cell source are the same. File your IND with that framework and you clear years of redundant testing.